ACC Media Center/X
Aug 29, 2025, 19:08
American College of Cardiology Highlights LoDoCo2 Trial on Colchicine, Blood Cancer Risk, and Heart Health
ACC (American College of Cardiology) Media Center posted on X:
”Taking low-dose colchicine daily may slow the progression of a common acquired gene mutation found in the blood of older adults that can lead to certain blood cancers and increased risk of cardiovascular disease, according to a subanalysis of the LoDoCo2 trial published in JACC and presented at ESC Congress.”
Read the full study here.
Stay updated with Hemostasis Today.
-
Nov 15, 2025, 12:24Thomas Reiser: Can AI Keep Up with Thrombosis Specialists?
-
Nov 15, 2025, 12:13Michael Makris on Immediate Suspension of Use of Plasma Derived FIX Concentrates in Punjab
-
Nov 15, 2025, 09:32Tushar Pandey: Hounoured to Be Part of Hematocon 2025
-
Nov 15, 2025, 09:11Lisa Murphy invites You to Join Her at Stroke Foundation’s Run4Stroke Marathon
-
Nov 15, 2025, 08:56Ahmed Bennis on Potential Use of P2Y12 Inhibitors as Safer Alternative in Monotherapy
-
Nov 15, 2025, 08:39Marika Nöjd: Donating Blood is An Easy Way to Do Good!
-
Nov 15, 2025, 08:19Joseph Caprini Released His UIP 2025 Session on VTE Recurrence Risk
-
Nov 15, 2025, 07:14Paul Bolaji Invites You to ”Thrombolytic Therapy in Acute Stroke in African Patients” Seminar
-
Nov 15, 2025, 07:03Carla Goulart Peron Explores The Role of Technology and Collaboration in Global Stroke Action